DSNKY: Daiichi Sankyo insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
8 institutions reported holding $3.38M of Daiichi Sankyo on Form 13F (9 the quarter before). 0 opened a new position and 1 sold out. Shares held by institutions: -42%.
| Largest holders | Shares | Value |
|---|---|---|
| Madison Asset Management, LLC | 157,556 | $2.55M |
| RHUMBLINE ADVISERS | 44,992 | $728K |
| GAMMA Investing LLC | 3,756 | $61K |
| Salomon & Ludwin, LLC | 1,373 | $22K |
| First Command Advisory Services, Inc. | 874 | $14K |
| PNC Financial Services Group, Inc. | 269 | $4K |
| Ramirez Asset Management, Inc. | 54 | $860 |
| IMA Advisory Services, Inc. | 52 | $841 |
Clinical trial readouts
7 Phase 2 or 3 trials by Daiichi Sankyo with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-08-31 (est.) | Trastuzumab deruxtecan | Gastric Cancer, Adenocarcinoma | Phase 3 | 490 | Enrollment complete | NCT04704934 |
| 2027-01-31 (est.) | DS-5141b | Duchenne Muscular Dystrophy | Phase 2 | 8 | Enrollment complete | NCT04433234 |
| 2027-04-30 (est.) | Ifinatamab deruxtecan (I-DXd) | Advanced Solid Tumor | Phase 1/2 | 247 | Enrollment complete | NCT04145622 |
| 2027-05-01 (est.) | Quizartinib | Acute Myeloid Leukemia | Phase 1/2 | 65 | Enrollment complete | NCT03793478 |
| 2027-07-20 (est.) | Ifinatamab deruxtecan | Extensive Stage-small Cell Lung Cancer | Phase 1/2 | 123 | Recruiting | NCT06362252 |
| 2027-09-01 (est.) | HER3-DXd | Advanced Solid Tumor | Phase 2 | 740 | Recruiting | NCT06172478 |
| 2027-10-01 (est.) | Trastuzumab Deruxtecan | Breast Cancer | Phase 3 | 250 | Recruiting | NCT05950945 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.